Skip to content
The Policy VaultThe Policy Vault

Zelsuvmi (berdazimer)Highmark

molluscum contagiosum

Initial criteria

  • age ≥ 1 year
  • diagnosis of molluscum contagiosum (ICD-10: B08.1)

Reauthorization criteria

  • prescriber attests that the member has previously experienced complete or partial clearance of molluscum contagiosum lesions with Zelsuvmi
  • prescriber attests that an additional course of therapy is required for recurrence of molluscum contagiosum

Approval duration

12 weeks